This is a case-based activity that includes discussion of two patients with triple negative breast cancer. The first is a 34-year-old woman who presented with a 6cm mass in the upper outer quadrant of her left breast. On exam, she was noted to have two palpable 2cm hard left axillary lymph nodes. A biopsy of the breast mass reveals grade 3 invasive ductal breast cancer, ER 0, PR 0, HER2 1+ and FISH negative. PET CT scan shows no evidence of metastatic disease outside of the left axillary and subpectoral lymph nodes.
The second patient is a 42-year-old woman with an enlarging breast mass and breast erythema. Imaging reveals an 8 x 9 cm mass with skin induration and questionable abnormal nodes. Biopsy reveals high grade invasive ductal cancer.
- Review the evidence supporting current systemic therapy options for early stage triple negative breast cancer
- Discuss systemic therapies that can improve disease-free survival in patients with locally advanced triple negative breast cancer
- Evaluate the standard and emerging therapies of benefit for patients with metastatic triple negative breast cancer
Continuing Education Credit
1 Credit/Point is available for participation in this course. Certificate and credit types available include:
- AMA PRA Category 1 Credits™
- ABIM MOC Points
- CNE Contact Hours
- CPE Credits
- Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
- Certificate of Completion may be used to document participation, but no credit will be conferred.
- This course expires on April 26, 2020. Participants must complete all necessary course components by this date.
- This course is also available as part of the 2017 ASCO Tumor Boards bundle.